Bodak 1989.

Methods	Prospective, randomized, double‐blind, placebo‐controlled study
Participants	132 participants aged more than 60 years with diastolic arterial pressure over 95mmHg and systolic over 160 mmHg. 62.9% participants were aged over 75 years. Mean age was 73.6 years; male 32/60 (53.3%) Baseline SBP/DBP with SD1 Placebo = 173.2 ± 14.7/104.7 ± 6.9 mmHg Cicletanine 150 mg = 176.3 ± 10.7/103.2 ± 7.6 mmHg Heart rate: placebo = 75.8 ± 6.7 and cicletanine = 76.9 ± 9
Interventions	Study A: cicletanine 150 mg per day and placebo for a duration of 180 days cicletanine 150 mg = 30 and placebo = 30 Study B: cicletanine 50 mg and cicletanine 100 mg with no parallel placebo arm, so this study was excluded from the review.
Outcomes	Systolic blood pressure, diastolic blood pressure Normalization of blood pressure Serum sodium, potassium, glucose, uric acid, creatinine, cholesterol, and triglycerides
Notes	Article in French translated by Ciprian Jauca. End‐of‐treatment SBP/DBP ± SD were reported in table III page 104. Withdrawal due to adverse events reported in Study A: 2 participants left in placebo group due to serious adverse events. Biochemical parameters at baseline and end of treatment with SD were reported in table V page 105. Change from baseline to end point in SBP, DBP, and biochemical values was calculated and SD at end of treatment was imputed for meta‐analysis.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described in the publication.
Allocation concealment (selection bias)	Unclear risk	Not described in the publication.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Not described in the publication.
Incomplete outcome data (attrition bias) All outcomes	Low risk	"14 patients left the study early," 12 from the excluded Study B and 2 from the included Study A (both from the placebo group, both due to serious adverse events).
Selective reporting (reporting bias)	Low risk	All outcome measures were reported.
Other bias	Unclear risk	The authors did not declare sponsorship or funding of this study and conflicts of interest in the publication.